Propafenone
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
The txgnn-pipeline skill is noted. This task is report generation from an Evidence Pack, so I'll proceed directly to produce the structured Markdown evaluation report.
Propafenone: From Cardiac Arrhythmia to Manic Bipolar Affective Disorder
One-Sentence Summary
Propafenone is a Class IC antiarrhythmic agent used clinically to manage cardiac arrhythmias including atrial fibrillation and ventricular tachycardia. The TxGNN model predicts it may be effective for Manic Bipolar Affective Disorder, with 0 clinical trials and 3 publications in the dataset — however, these publications describe adverse events and drug interactions rather than any therapeutic use. At this stage, this prediction is considered mechanistically implausible and the overall recommendation is Hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cardiac Arrhythmia (Class IC Antiarrhythmic; no Italy regulatory record available) |
| Predicted New Indication | Manic Bipolar Affective Disorder |
| TxGNN Prediction Score | 99.80% |
| Evidence Level | L5 |
| Italy Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, propafenone is a Class IC antiarrhythmic agent that primarily blocks cardiac sodium channels (Nav1.5). It also possesses mild beta-adrenergic blocking and weak calcium channel antagonist properties. Crucially, its CNS penetration is very low due to insufficient lipophilicity — and no known mood-stabilizing or anti-manic mechanism has been identified for this drug.
Cardiac arrhythmia and manic bipolar affective disorder are mechanistically unrelated conditions. The TxGNN model appears to have misidentified a co-occurrence signal in its knowledge graph: the available "supporting" literature describes propafenone causing mania as an adverse effect (PMID 2579063) and documents harmful interactions between cardiovascular drugs and antipsychotics (PMID 32124390) — not evidence of therapeutic benefit in bipolar disorder. This is a known failure mode in graph-based models, where causal direction between a drug node and disease node is not properly resolved.
In summary, this rank-1 prediction does not have a biologically plausible rationale. The model has conflated an adverse event relationship (propafenone → mania) with a therapeutic one. No additional investigation for this indication is recommended.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
⚠️ Important caveat: The publications below do not support propafenone as a treatment for bipolar disorder. They document adverse events and drug interactions. They appear in this dataset because propafenone and bipolar disorder co-occur in a safety context, not a therapeutic one.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32124390 | 2020 | Review | Pharmacological Reports | Evaluates harmful interactions between antipsychotics and cardiovascular medications; does not support propafenone as a treatment for bipolar disorder |
| 11949740 | 2001 | Case Report | Int J Psychiatry in Medicine | Reports a case of organic psychosis resulting from a venlafaxine–propafenone drug interaction in a bipolar patient — this is an adverse event, not a therapeutic application |
| 2579063 | 1985 | Case Report | J Clin Psychiatry | Describes mania induced by propafenone administration; notes chemical similarity to bupropion (antidepressant) as a possible mechanism of psychiatric side effects |
Safety Considerations
Please refer to the package insert for safety information.
Summary of All Predicted Indications
For context, the following table summarises all 8 TxGNN-predicted indications and their evidence status:
| Rank | Disease | TxGNN Score | Evidence Level | Decision |
|---|---|---|---|---|
| 1 | Manic Bipolar Affective Disorder | 99.80% | L5 | Hold — adverse event misread as therapeutic |
| 2 | Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) | 99.79% | L3 | Proceed with Guardrails — direct RyR2 inhibition mechanism; 9 publications |
| 3 | Periodic Paralysis with Transient Compartment-like Syndrome | 99.67% | L5 | Hold — channel selectivity mismatch (Nav1.5 vs Nav1.4) |
| 4 | Prinzmetal Angina | 99.45% | L5 | Hold — Class IC agents may worsen ischaemia-related arrhythmia |
| 5 | Incessant Infant Ventricular Tachycardia | 99.44% | L3 | Proceed with Guardrails — paediatric use on record since 1987; 5 publications |
| 6 | Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) | 99.42% | L3 | Research Question — proarrhythmia risk in structural heart disease; 12 publications |
| 7 | Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD) | 99.23% | L5 | Hold — no mechanistic intersection |
| 8 | Trichotillomania | 99.17% | L5 | Hold — peripheral cardiac drug; negligible CNS penetration |
The most scientifically compelling repurposing candidate is CPVT (Rank 2): propafenone directly inhibits RyR2 calcium release channels — the primary pathological driver in CPVT — while its Nav1.5 blockade and mild beta-blocking properties provide complementary suppression of triggered arrhythmias.
Conclusion and Next Steps
Decision: Hold (for Rank 1: Manic Bipolar Affective Disorder)
Rationale: The TxGNN rank-1 prediction is mechanistically implausible. Propafenone's very low CNS penetration, absence of any mood-stabilizing pathway, and the fact that the only available literature documents propafenone causing psychiatric adverse effects collectively make this a clear false positive. The model appears to have reversed the causal direction of a known adverse drug reaction.
To proceed with further evaluation:
- Do not pursue manic bipolar affective disorder as a repurposing target for propafenone
- Recommended pivot: Initiate a full evidence synthesis for CPVT (Rank 2), which has mechanistic grounding (RyR2 inhibition, PMID 21270101, 26121139), observational cohort support, and a long-term case report of 35-year successful treatment (PMID 30820400)
- Obtain package insert / regulatory data: Retrieve Italy (AIFA) and Taiwan (TFDA) prescribing information to fill the safety data gap before any clinical planning
- Obtain formal MOA documentation: Query DrugBank API for DB01182 to complete mechanism-of-action analysis
- For ARVC (Rank 6): Commission a systematic safety review specifically examining Class IC proarrhythmia risk in structural heart disease before proceeding further
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.